新型广谱头孢菌素类抗生素头孢洛林酯  

A novel broad-spectrum cephalosporin ceftaroline fosamil

作　　者：马帅[1] 袁红[1] 赵俊[1] 曹胜华[1] 

机构地区：[1]四川抗菌素工业研究所,成都610052

出　　处：《中国抗生素杂志》2015年第2期145-153,共9页Chinese Journal of Antibiotics

摘　　要：近年来新抗生素上市缓慢和耐药菌迅速发展使临床抗感染治疗愈加困难。头孢洛林酯是第一个被FDA批准上市的广谱的、具有抗MRSA感染的头孢类抗生素,2012年又获得欧盟委员会的批准上市,用于治疗成人复杂性皮肤和软组织感染和社区获得性肺炎。现对其作用机制、合成路线、体外抗菌活性、药动学和药效学性质、临床试验等方面作一综述。In recent years new antibiotics have been approved slowly with the growing prevalence of drugresistant bacteria pose a dilemma to treat in clinic. Ceftaroline fosamil is the first broad-spectrum cephalosporin that has been approved by FDA with anti-MRSA infection. The European Commission granted marketing authorization for ceftaroline fosamil in 2012 for the treatment of adults with complicated skin and soft tissue infections and communityacquired pneumonia. The review summarizes its mechanism of action, synthetic routes, in vitro antibacterial activity, pharmacokinetics and pharmacodynamics, and clinical trials.

关 键 词：头孢洛林酯 合成路线 抗菌活性 临床试验 

分 类 号：R978.11[医药卫生—药品]